Imagion Biosystems Ltd. · ASX:IBX
Imagion Biosystems — Switzer Small and Microcap - Virtual Investor Day, December 2020
16 slides from Imagion Biosystems's conference presentation, December 2020
Slide 1: Switzer Small and Microcap - Virtual Investor Day, December 2020
® B I O S Y S T E M S Switzer Small and Microcap - Virtual Investor Day, December 2020 ASX:IBX www.imagionbiosystems.com
Slide 2: Disclaimer
DISCLAIMER This investor presentation (Presentation) has been prepared by Imagion Biosystems Limited (Imagion or the Company). This presentation does not constitute or form part of, and should not be construed as, an offer, solicitation or invitation to subscribe for, underwrite or otherwise acquire
Slide 3: Imagion Biosystems At-a-Glance
I M A G I O N B I O S Y S T E M S AT- A - G L A N C E New medical imaging technologies for the early detection of cancer Imagion Biosystems • Innovative medical imaging using magnetic nanoparticles to identify and ASX:IBX Australian Medical Device Company stage cancer early developing bio-safe medic
Slide 4: A Growing Global Health Problem
A G R O W I N G G L O B A L H E A LT H P R O B L E M 1 in 3 people are affected by cancer $100B CANCER DIAGNOSTICS MARKET Each year cancer kills $30,000 $26,044 9 million people $25,000 $20,000 $20,136 $100B spent annually Millions (USD) $15,541 to diagnose or detect $15,000 cancer, yet cancer $10,0
Slide 5: Clear Unmet Medical Need
CLEAR UNMET MEDICAL NEED 50 years since last new imaging technology was introduced X-RAY ULTRASOUND MAGNETIC RESONANCE COMPUTED POSITRON EMISSION TOMOGRAPHY (MAMMOGRAPHY) 1956 (MRI) TOMOGRAPHY (CT) (PET) 1913 1971 1972 1973 • Best used for • Inexpensive and fast • Best for imaging soft • Better for
Slide 6: Medical Imaging Breakthrough
MEDICAL IMAGING BREAKTHROUGH MagSense™ Technology will transform cancer diagnosis • Non-invasive – a safe and non-surgical solution to detect cancer • No radioactivity - uses bio-safe magnetic nanoparticles to “tag” cancer cells • Platform technology – can be used for many cancers as well as other d
Slide 7: Improving Outcomes
IMPROVING OUTCOMES Better sensitivity could mean earlier detection MagSense™ technology is expected to have sensitivity comparable to PET without use of radioactivity, making it better for routine use in early detection and resulting in more successful treatments and patient outcomes. SURVIVAL RATE
Slide 8: Transformative for Medical Imaging
T R A N S F O R M AT I V E F O R M E D I C A L I M A G I N G Designated by FDA as a “Breakthrough Device” The MagSense™ HER2 Metastatic Breast Cancer Test • Works within current standard cancer diagnosis and staging protocols. • Replaces current non-functional imaging such as MRI or ultrasound used
Slide 9: Broad Commercial Applicability
BROAD COMMERCIAL APPLICABILITY Can be used for many types of cancer and at multiple stages of diagnosis MAGSENSE NANOPARTICLES MULTIPLE CLINICAL TARGETS • Are bio-functionalized to ensure high specificity for targeting different types of cancers, or other diseases. • Can be used at multiple stages i
Slide 10: Compelling Business Model
COMPELLING BUSINESS MODEL Proprietary consumable drives growth & profitability US Patent 9095270 - Detection, measurement, & imaging of cells such as cancer & other biological substances using targeted nanoparticle & magnetic properties thereof Licensing or Commercial Lower Cost Capital Sale Partner
Slide 11: Achievements and Next Steps
ACHIEVEMENTS AND NEXT STEPS Phase I Study for HER2 Metastatic Breast Cancer Achievements in 2019-20 ü GLP Toxicity study completed ü FDA “Breakthrough Device” designation Phase I Study Multi-Site in AUS Timing ü Scientific Advisory Board established • Primary endpoint • 3-5 clinical sites • Enrolmen
Slide 12: A Platform for Growth
A P L AT F O R M F O R G R O W T H Significant opportunities in biomedical applications of magnetic nanoparticles CANCER SCREENING Magnetic nanoparticles are used to collect/separate tumor cells and cancer DNA from blood • Breast Cancer DIAGNOSTIC IMAGING MagSense nanoparticles are • Prostate Cancer
Slide 13: Investment Rationale
I N V E S T M E N T R AT I O N A L E Strategic plan provides path to future products & shareholder value STAGING TUMOR MRI TREATMENT DOCTORS DETECTION & BREAST CANCER DETECTION CONTRAST MONITORING OFFICE THERAPY Reduce unnecessary Breast, prostate, lung Safer alternative to Monitor tumor size Hand-h
Slide 14: Capital Structure
C A P I TA L S T R U C T U R E No debt, one class of common stock Share price – Last 12 months Ordinary shares on issue 911.72M Price (AUD) Share price 0.15 $0.15 (24 November 2020) $0.13 Average daily volume 11.3M (as of 24 November 2020) $0.11 Market capitalization 136.75 $0.09 (24 November 2020)
Slide 15: Investment Highlights
INVESTMENT HIGHLIGHTS LARGE OPPORTUNITY UNIQUE TECHNOLOGY $100B cancer diagnostic market New form of medical imaging Growing 7% annually Molecularly specific & non-invasive Medical imaging commands largest share More sensitive than current methods Huge medical need for early diagnosis Protected by e
Slide 16: Contact
® B I O S Y S T E M S Contact: www.imagionbiosystems.com info@imagionbio.com ASX: IBX
Imagion Biosystems — Switzer Small and Microcap - Virtual Investor Day, December 2020 on 6ix